# NEUROONE MEDICAL TECHNOLOGIES Corp: overview NMTC · Nasdaq · CIK 1500198 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Sep 30 Pages: [Overview](/companies/nmtc.md) · [Financials](/companies/nmtc/financials.md) · [Filings](/companies/nmtc/filings.md) · [Insiders](/companies/nmtc/insiders.md) Latest reported revenue: [$2.0m](/filings/0001213900-26-088724.md) for Q3 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:Revenues, accession 0001213900-26-088724). ## Last eight quarters | Line item | Unit | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [272 d](/filings/0001213900-25-122390.md) | [3,274](/filings/0001213900-26-016860.md) | [1,387](/filings/0001213900-26-068307.md) | [1,696](/filings/0001213900-26-088724.md) | [2,741 d](/filings/0001213900-25-122390.md) | [2,893](/filings/0001213900-26-016860.md) | [1,862](/filings/0001213900-26-068307.md) | [1,973](/filings/0001213900-26-088724.md) | | Gross margin | % | [51.8% d](/filings/0001213900-25-122390.md) | [58.9%](/filings/0001213900-26-016860.md) | [55.6%](/filings/0001213900-26-068307.md) | [53.9%](/filings/0001213900-26-088724.md) | [55.8% d](/filings/0001213900-25-122390.md) | [54.2%](/filings/0001213900-26-016860.md) | [53.2%](/filings/0001213900-26-068307.md) | [59.9%](/filings/0001213900-26-088724.md) | | Operating margin | % | [(1034.5%) d](/filings/0001213900-25-122390.md) | [52.3%](/filings/0001213900-26-016860.md) | [(193.3%)](/filings/0001213900-26-068307.md) | [(111.2%)](/filings/0001213900-26-088724.md) | [(50.0%) d](/filings/0001213900-25-122390.md) | [(59.0%)](/filings/0001213900-26-016860.md) | [(128.7%)](/filings/0001213900-26-068307.md) | [(122.9%)](/filings/0001213900-26-088724.md) | | Net margin | % | [(1230.6%) d](/filings/0001213900-25-122390.md) | [54.5%](/filings/0001213900-26-088724.md) | [(163.8%)](/filings/0001213900-26-088724.md) | [(88.5%)](/filings/0001213900-26-088724.md) | [(59.1%) d](/filings/0001213900-25-122390.md) | [(49.7%)](/filings/0001213900-26-088724.md) | [(127.9%)](/filings/0001213900-26-088724.md) | [(101.7%)](/filings/0001213900-26-088724.md) | | Diluted EPS | $ per share | not reported | [0.06](/filings/0001213900-26-016860.md) | [(0.44)](/filings/0001213900-26-068307.md) | [(0.19)](/filings/0001213900-26-088724.md) | not reported | [(0.03)](/filings/0001213900-26-016860.md) | [(0.28)](/filings/0001213900-26-068307.md) | [(0.28)](/filings/0001213900-26-088724.md) | | Free cash flow | $k | [(2,704) d](/filings/0001213900-25-122390.md) | [184](/filings/0001213900-26-016860.md) | [(59.3) d](/filings/0001213900-26-068307.md) | [(1,507) d](/filings/0001213900-26-088724.md) | [(1,536) d](/filings/0001213900-25-122390.md) | [(3,157)](/filings/0001213900-26-016860.md) | [(1,367) d](/filings/0001213900-26-068307.md) | [(1,101) d](/filings/0001213900-26-088724.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-09-30) | FY2022 (2022-09-30) | FY2023 (2023-09-30) | FY2024 (2024-09-30) | FY2025 (2025-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.2](/filings/0001213900-22-081897.md) | [0.2](/filings/0001213900-23-096120.md) | [2.0](/filings/0001213900-24-109524.md) | [3.5](/filings/0001213900-25-122390.md) | [9.1](/filings/0001213900-25-122390.md) | | Gross margin | % | [(54.9%)](/filings/0001213900-22-081897.md) | [(41.4%)](/filings/0001213900-23-096120.md) | [23.4%](/filings/0001213900-24-109524.md) | [31.3%](/filings/0001213900-25-122390.md) | [56.5%](/filings/0001213900-25-122390.md) | | Operating margin | % | [(5735.9%)](/filings/0001213900-22-081897.md) | [(5860.2%)](/filings/0001213900-23-096120.md) | [(612.3%)](/filings/0001213900-24-109524.md) | [(344.3%)](/filings/0001213900-25-122390.md) | [(46.5%)](/filings/0001213900-25-122390.md) | | Net margin | % | [(5584.3%)](/filings/0001213900-22-081897.md) | [(5842.0%)](/filings/0001213900-23-096120.md) | [(607.4%)](/filings/0001213900-24-109524.md) | [(356.7%)](/filings/0001213900-25-122390.md) | [(39.6%)](/filings/0001213900-25-122390.md) | | Diluted EPS | $ per share | [(0.93)](/filings/0001213900-22-081897.md) | [(0.63)](/filings/0001213900-23-096120.md) | [(0.65)](/filings/0001213900-24-109524.md) | [(0.46)](/filings/0001213900-25-122390.md) | [(0.09)](/filings/0001213900-25-122390.md) | | Free cash flow | $m | [(8.7)](/filings/0001213900-22-081897.md) | [(7.8)](/filings/0001213900-23-096120.md) | [(13.3)](/filings/0001213900-24-109524.md) | [(11.1)](/filings/0001213900-25-122390.md) | [(2.9)](/filings/0001213900-25-122390.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/nmtc/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Bleichroeder LP](/funds/1781002.md) | 2026-06-30 | $2.0m | 666,666 | | New +666,666 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.1m | 352,774 | | New +352,774 | | [BARD ASSOCIATES INC](/funds/1105907.md) | 2026-06-30 | $928.5k | 305,428 | | New +305,428 | | [PERKINS CAPITAL MANAGEMENT INC](/funds/884300.md) | 2026-06-30 | $743.8k | 244,656 | | New +244,656 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $284.4k | 93,555 | | New +93,555 | | [Sio Capital Management, LLC](/funds/1482416.md) | 2026-06-30 | $251.6k | 82,767 | | New +82,767 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $215.4k | 70,861 | | New +70,861 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $149.0k | 49,018 | | New +49,018 | | [ESSEX INVESTMENT MANAGEMENT CO LLC](/funds/201772.md) | 2026-06-30 | $132.5k | 43,578 | | New +43,578 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $76.4k | 25,121 | | New +25,121 | ## Recent filings [All 653 filings](/companies/nmtc/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-05 | 13:20 ET | [8-K](/filings/0001213900-26-106677.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-106677 | | 2026-08-27 | 13:05 ET | [8-K](/filings/0001213900-26-094174.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-094174 | | 2026-08-13 | 12:20 ET | [10-Q](/filings/0001213900-26-088724.md) | Quarterly report, period 2026-06-30 | 0001213900-26-088724 | | 2026-08-13 | 12:15 ET | [8-K](/filings/0001213900-26-088719.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-26-088719 | | 2026-06-12 | 20:45 ET | [8-K](/filings/0001213900-26-068327.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-068327 | | 2026-06-12 | 20:32 ET | [10-Q/A](/filings/0001213900-26-068307.md) | Quarterly report, amended, period 2026-03-31 | 0001213900-26-068307 | | 2026-05-22 | 20:30 ET | [8-K](/filings/0001213900-26-060600.md) | 4.02 Non-reliance on financial statements; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-060600 | | 2026-05-12 | 12:15 ET | [10-Q](/filings/0001213900-26-054749.md) | Quarterly report, period 2026-03-31 | 0001213900-26-054749 | | 2026-05-12 | 12:10 ET | [8-K](/filings/0001213900-26-054744.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-26-054744 | | 2026-05-04 | 12:30 ET | [8-K](/filings/0001213900-26-051158.md) | 8.01 Other events | 0001213900-26-051158 | ## Latest annual report [Form 10-K for the fiscal year ended Sep 30, 2025](/filings/0001213900-25-122390.md), filed Dec 17, 2025. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1500198 - Tickers: NMTC - Exchange: Nasdaq - SIC code: 3841 Surgical & Medical Instruments & Apparatus - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.